Cleveland Clinic Abu Dhabi honours 600+ caregivers for decade of dedication
ABU DHABI (ALETIHAD)Continuing its 10-year anniversary celebrations, Cleveland Clinic Abu Dhabi hosted a special event to honour more than 600 founding caregivers who have completed over 10 years of service at the organisation.The recognition ceremony was held to honour their dedication and commitment, which helped bring the hospital's vision to life: being the best place to receive care and the best place to work in healthcare. Since opening its doors in 2015, Cleveland Clinic Abu Dhabi has grown into a thriving community of over 5,700 caregivers from over 80 nationalities. The hospital's team includes over 590 physicians, 1,700 nurses, and 590 allied health professionals.Over its first decade, Cleveland Clinic Abu Dhabi has recorded over 6.8 million patient encounters and performed more than 174,000 complex surgeries, redefining healthcare in the UAE and the wider region by delivering world-class expertise, advanced treatments, and compassionate care, all closer to home. Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, said: "Our caregivers have been central to our tripartite mission of providing compassionate, complex care, research for health, and educating those who serve. Together, they have helped build a hospital trusted by thousands of patients in Abu Dhabi, and beyond."As we celebrate our achievements over the years, we also celebrate the caregivers who have been with us from the very beginning. Their unwavering commitment to our patients and the community has pushed boundaries in innovation and shaped the care we deliver today. Looking ahead, we remain steadfast in delivering world-class care, expanding our impact, and setting new benchmarks in healthcare for Abu Dhabi and the world."By offering patients in the UAE access to the highest levels of specialised care, Cleveland Clinic Abu Dhabi has significantly reduced the need for outbound medical travel over the past decade. This remarkable transformation has raised the standard of care locally and firmly positioned Abu Dhabi as a global healthcare hub, welcoming more than 10,000 international patients, he added.Mariam Al Mujaini, manager of patient experience, at Cleveland Clinic Abu Dhabi and one of the celebrated caregivers, commented: "In 2014, I embarked on my journey at Cleveland Clinic Abu Dhabi, and being part of this remarkable organization from the beginning has been an incredible, rewarding experience. As an Emirati woman, leading patient experience, I am proud to have contributed to creating a compassionate, world-class healthcare environment that not only enhances lives but also gives back to my country by raising healthcare standards across the UAE and beyond.'Zeina Kassem, nursing director for the Oncology and Organ Transplant programmes, said: "Working at Cleveland Clinic Abu Dhabi for the past 10 years has been an incredible journey, both professionally and personally. This hospital truly stands out for its unwavering commitment to patient care and teamwork.As a leader, I witnessed the life-changing impact we've had on patients and their families.
"Transforming this place from just an idea into a fully functional hospital with all its centers of excellence, like the cancer center, transplant programme, and all the others, has been so rewarding. I am incredibly proud to be part of an institution that not only heals patients but nurtures its people. It's been a privilege to grow and contribute to this journey.''
Source: Aletihad - Abu Dhabi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
an hour ago
- Al Etihad
Cleveland Clinic Abu Dhabi receives global recognition for nursing excellence
7 Aug 2025 13:58 ABU DHABI (ALETIHAD) Cleveland Clinic Abu Dhabi (CCAD) has received two international honours for nursing excellence. Four of its acute care units were awarded the PRISM Award by the Academy of Medical-Surgical Nurses, and its Intensive Care Unit received the renowned Beacon Award for Excellence from the American Association of Critical-Care Nurses. These awards reflect the hospital's continuous commitment to high-quality care and advanced nursing practices that ensure the best outcomes for Clinic Abu Dhabi is the first hospital in the UAE, and only the fourth outside the United States, to receive the PRISM Award, setting a new benchmark for nursing excellence in the region. This milestone highlights not only the hospital's clinical strength but also the calibre of its nursing leadership, professional practice, and commitment to development, empowerment, and a collaborative environment where nurses can hospital's Intensive Care Unit also received the Beacon Award for Excellence, a distinction that recognises hospital units that employ evidence-based practices to improve outcomes for patients and families. The Beacon Award reflects the high standards upheld by Cleveland Clinic Abu Dhabi's critical care the vital role nurses play within the healthcare system, Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, emphasised: 'Nurses are the backbone of quality healthcare. At Cleveland Clinic Abu Dhabi, our nurses combine compassion with clinical expertise and the latest innovations to deliver care that truly changes lives. Their dedication to improving outcomes and elevating the patient's experience is what sets our care apart. These awards are not just acknowledgements; they reflect the trust our patients place in us every day, and the continuous drive of our nursing team to raise the bar in healthcare delivery.'Beth Govero, Chief Nursing Officer, Cleveland Clinic Abu Dhabi, said: 'These distinguished international recognitions stand as a testament to the expertise, perseverance, and passion of our nursing team. Nurses form the cornerstone of effective healthcare delivery, and their relentless pursuit of quality ensures exceptional care for every patient. These recognitions celebrate not only their hard work but also our collective efforts to create a supportive environment where nurses are empowered to lead, innovate, and continually advance patient care here in the UAE and beyond.'Last year, Cleveland Clinic Abu Dhabi was redesignated with the coveted Magnet® designation from the American Nurses Credentialing Centre (ANCC). Widely regarded as the gold standard for nursing excellence, this recognition highlights the hospital's commitment to transformational leadership, innovation in clinical practice, and a culture that prioritises professional development and patient-centred care. Cleveland Clinic Abu Dhabi was the first and the youngest hospital in the UAE to receive this designation in the same year, the hospital hosted its inaugural Nursing Conference, a pivotal event that brought together nursing professionals from across the region to deepen their expertise and strengthen their practice. By fostering meaningful knowledge exchange and collaboration, the conference empowered registered nurses, nurse practitioners, midwives, and clinical specialists to expand their skills and engage with leading international experts, reinforcing their essential role in delivering exceptional patient care. Building on that success, the hospital will host the second conference later this November, reinforcing its commitment to advancing nursing excellence. Cleveland Clinic Abu Dhabi is dedicated to nursing excellence and achieving superior patient outcomes. As it continues to advance this mission, it remains committed to empowering nurses as the cornerstone of transformative, patient-centred care. Source: Aletihad - Abu Dhabi
Al Etihad
16 hours ago
- Al Etihad
Harvard research on reversing Alzheimer's reveals lithium as potential key
6 Aug 2025 22:51 ABU DHABI (ALETIHAD)A decade of investigation by scientists at Harvard Medical School have revealed that the loss of the metal lithium plays a powerful role in Alzheimer's disease, a finding that could lead to earlier detection and new treatments for the disease that affects memory and cognitive led by Bruce A. Yankner, professor of genetics and neurology at Harvard Medical School, reported that they were able to reverse the disease in mice and restore brain function with small amounts of the compound lithium orotate, enough to mimic the metal's natural level in the brain. Their study appeared Wednesday in the journal findings are based on a series of experiments in mice and on analyses of human brain tissue and blood samples from individuals in various stages of cognitive scientists found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, similar lithium depletion accelerated brain pathology and memory team further found that reduced lithium levels stemmed from binding to amyloid plaques and impaired uptake in the brain. In a final set of experiments, the team found that a novel lithium compound that avoids capture by amyloid plaques restored memory in mice. The results unify decades-long observations in patients, providing a new theory of the disease and a new strategy for early diagnosis, prevention, and an estimated 400 million people worldwide, Alzheimer's disease involves an array of brain abnormalities — such as clumps of the protein amyloid beta, neurofibrillary tangles of the protein tau, and loss of a protective protein called REST — but these never explained the full story of the instance, some people with such abnormalities show no signs of cognitive decline. And recently developed treatments that target amyloid beta typically don't reverse memory loss and only modestly reduce the rate of decline. It is also clear that genetic and environmental factors affect risk of Alzheimer's, but scientists haven't figured out why some people with the same risk factors develop the disease while others do not. Lithium, the study authors said, may be a critical missing link.'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' said senior author Bruce Yankner, professor of genetics and neurology in the Blavatnik Institute at HMS, who in the 1990s was the first to demonstrate that amyloid beta is study raises hopes that researchers could one day use lithium to treat the disease in its entirety rather than focusing on a single facet such as amyloid beta or tau, he of the main discoveries in the study is that as amyloid beta begins to form deposits in the early stages of dementia in both humans and mouse models, it binds to lithium, reducing lithium's function in the brain. The lower lithium levels affect all major brain cell types and, in mice, give rise to changes recapitulating Alzheimer's disease, including memory authors identified a class of lithium compounds that can evade capture by amyloid beta. Treating mice with the most potent amyloid-evading compound, called lithium orotate, reversed Alzheimer's disease pathology, prevented brain cell damage, and restored the findings need to be confirmed in humans through clinical trials, they suggest that measuring lithium levels could help screen for early Alzheimer's. Moreover, the findings point to the importance of testing amyloid-evading lithium compounds for treatment or lithium compounds are already used to treat bipolar disorder and major depressive disorder, but they are given at much higher concentrations that can be toxic, especially to older team found that lithium orotate is effective at one-thousandth that dose — enough to mimic the natural level of lithium in the brain. Mice treated for nearly their entire adult lives showed no evidence of lithium has not yet been shown to be safe or effective in protecting against neurodegeneration in humans, Yankner emphasises that people should not take lithium compounds on their own. But he expressed cautious optimism that lithium orotate or a similar compound will move forward into clinical trials in the near future and could ultimately change the story of Alzheimer's treatment. 'My hope is that lithium will do something more fundamental than anti-amyloid or anti-tau therapies, not just lessening but reversing cognitive decline and improving patients' lives,' he said. Source: Aletihad - Abu Dhabi
Al Etihad
a day ago
- Al Etihad
Cleveland Clinic Abu Dhabi introduces aquablation therapy for Benign Prostatic Hyperplasia
6 Aug 2025 12:26 ABU DHABI (ALETIHAD)In a groundbreaking advancement for prostate treatment, Cleveland Clinic Abu Dhabi has introduced aquablation therapy, a cutting-edge, minimally invasive procedure that brings new hope for men suffering from Benign Prostatic Hyperplasia (BPH). This innovative therapy is the first in the UAE to use a robotic-assisted waterjet solution for BPH, providing a new benchmark in precision and safety through real-time ultrasound guidance and robotic control, without the potential risks associated with heat-based to global studies, nearly 50% of men over the age of 60 are affected by BPH, with the prevalence rising to around 80% by age 85. The condition can lead to frequent urination, weak urinary flow, and, in advanced cases, urinary retention or incontinence, significantly impacting a patient's quality of life. Traditional treatments like medication and Transurethral Resection of the Prostate (TURP) surgery, which removes excess prostate tissue, may involve longer recovery periods and potential side effects in some cases. Aquablation offers a minimally invasive, heat-free alternative with faster recovery and a lower risk of side on the adoption, Dr. Georges-Pascal Haber, Chief Executive Officer at Cleveland Clinic Abu Dhabi, and a leading urologist specialising in robotic surgery, said: 'At Cleveland Clinic Abu Dhabi, we are committed to continuously advancing our medical capabilities and ensuring that the latest technologies, like the aquablation therapy, are available to our patients." He added, "It represents another milestone in our pursuit of providing the highest standards of care to our patients. We are deeply grateful for the ongoing support from the Department of Health- Abu Dhabi, which enables us to deliver world-class healthcare solutions right here in Abu Dhabi.' Dr. Waleed Hassen, Department Chair of Urology in the Surgical Subspecialties Institute at Cleveland Clinic Abu Dhabi, added: 'Aquablation therapy represents a new era in the treatment of benign prostatic hyperplasia (BPH), addressing the limitations of traditional techniques with remarkable precision and safety. We chose to bring this technology to Cleveland Clinic Abu Dhabi because it aligns with our mission of providing the most advanced, patient-centred care. Unlike conventional methods, aquablation is ideal for patients with even the most challenging prostate conditions, offering a level of customisation and predictability that has not been possible before.'Aquablation therapy utilises the AquaBeam® Robotic System, which delivers a heat-free, high-pressure waterjet to precisely remove prostate tissue. Unlike traditional methods that use heat (such as laser or electrocautery-based techniques), the non-thermal waterjet technology ensures minimal damage to surrounding tissues, significantly lowering the risk of side effects such as incontinence or sexual treatment is guided by real-time ultrasound imaging and cystoscopy, which allow the surgeon to visualise critical structures, such as the bladder neck, verumontanum, and external sphincter, ensuring their preservation. This combination of robotic precision and advanced imaging helps optimise outcomes and minimise risks. Dr. Zaki Almallah, Staff Physician, Urology, Surgical Subspecialties Institute, Cleveland Clinic Abu Dhabi, explained: "Aquablation therapy is truly revolutionary in treating benign prostatic hyperplasia. It is a one-time procedure that provides long-lasting symptom relief, with patients enjoying the benefits for years after treatment. By harnessing the power of robotic technology, we can now offer patients a treatment that is both highly effective and minimally invasive. It's the only treatment that provides real-time imaging of the entire prostate, allowing us to precisely remove excess tissue while preserving reproductive function. This means patients experience fewer side effects, faster recovery and a significant improvement in quality of life."Dr. Omer Raheem, Staff Physician, Urology, Surgical Subspecialties Institute, Cleveland Clinic Abu Dhabi, added: 'The robotic precision in the aquablation is truly transformative, especially for patients with larger prostates where traditional methods often fall short. The average resection time with aquablation is just 5.8 minutes, compared to nearly half an hour for TURP, without compromising on safety or effectiveness. It's an advanced solution that minimises risk, accelerates recovery, and offers patients an unmatched standard of care.'Cleveland Clinic Abu Dhabi's introduction of aquablation therapy is a testament to offering advanced treatment, aligning with its mission to deliver world-class, innovative healthcare solutions. As part of its Urology Program, which already provides a wide range of surgical and non-surgical treatments for complex bladder, kidney, and prostate conditions, the addition of aquablation further enhances the hospital's comprehensive care offering. In addition to aquablation therapy, Cleveland Clinic Abu Dhabi recently introduced Focal One High-Intensity Focused Ultrasound (HIFU) for prostate cancer, a non-invasive procedure that uses ultrasound waves to target and destroy cancer cells with high precision. These advances highlight Cleveland Clinic Abu Dhabi's leadership in urological care, offering patients in the UAE access to cutting-edge treatments that significantly improve outcomes and quality of life. Source: Aletihad - Abu Dhabi
